Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Blood Pressure | 12 | 2019 | 2198 | 2.30 | Why? |
| Blood Pressure Determination | 5 | 2019 | 450 | 1.99 | Why? |
| Hypertension | 21 | 2021 | 8895 | 1.95 | Why? |
| Hypertrophy, Left Ventricular | 4 | 2019 | 219 | 1.92 | Why? |
| Pulse Wave Analysis | 2 | 2019 | 221 | 1.37 | Why? |
| Carotid Arteries | 2 | 2019 | 182 | 1.30 | Why? |
| Antihypertensive Agents | 9 | 2021 | 1962 | 0.97 | Why? |
| Carotid Intima-Media Thickness | 2 | 2019 | 179 | 0.89 | Why? |
| Ventricular Function, Left | 3 | 2018 | 1555 | 0.85 | Why? |
| Intracranial Hemorrhage, Hypertensive | 1 | 2018 | 4 | 0.76 | Why? |
| Retinal Artery | 1 | 2018 | 16 | 0.74 | Why? |
| Heart Rupture | 1 | 2018 | 14 | 0.73 | Why? |
| Vascular Stiffness | 2 | 2019 | 264 | 0.70 | Why? |
| Ventricular Remodeling | 2 | 2018 | 349 | 0.70 | Why? |
| Cocaine-Related Disorders | 1 | 2018 | 51 | 0.68 | Why? |
| Carotid Artery Diseases | 1 | 2018 | 251 | 0.57 | Why? |
| Terminology as Topic | 1 | 2018 | 546 | 0.49 | Why? |
| Heart Ventricles | 2 | 2019 | 1139 | 0.48 | Why? |
| Coronary Vessels | 1 | 2019 | 914 | 0.45 | Why? |
| Cardiovascular Agents | 1 | 2017 | 663 | 0.42 | Why? |
| Foramen Ovale, Patent | 1 | 2013 | 153 | 0.41 | Why? |
| Ventricular Dysfunction, Left | 1 | 2018 | 993 | 0.39 | Why? |
| Renal Insufficiency, Chronic | 3 | 2021 | 2654 | 0.36 | Why? |
| Emergency Service, Hospital | 3 | 2020 | 14232 | 0.27 | Why? |
| Kidney | 1 | 2018 | 3648 | 0.26 | Why? |
| Heart Failure | 4 | 2021 | 6638 | 0.25 | Why? |
| Echocardiography | 4 | 2019 | 3661 | 0.23 | Why? |
| Italy | 14 | 2021 | 38444 | 0.22 | Why? |
| Chlamydophila pneumoniae | 1 | 2021 | 98 | 0.21 | Why? |
| Angiotensin Receptor Antagonists | 3 | 2021 | 3892 | 0.20 | Why? |
| Antibodies, Anticardiolipin | 1 | 2020 | 208 | 0.19 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2021 | 5277 | 0.19 | Why? |
| Arterioles | 1 | 2018 | 24 | 0.19 | Why? |
| Vascular Remodeling | 1 | 2019 | 99 | 0.19 | Why? |
| Stroke | 2 | 2020 | 8839 | 0.18 | Why? |
| Pneumonia, Mycoplasma | 1 | 2021 | 292 | 0.17 | Why? |
| Risk Factors | 12 | 2021 | 71621 | 0.17 | Why? |
| Recovery of Function | 2 | 2018 | 2461 | 0.17 | Why? |
| Dihydropyridines | 1 | 2017 | 29 | 0.17 | Why? |
| Hydrochlorothiazide | 1 | 2017 | 31 | 0.17 | Why? |
| Enalapril | 1 | 2017 | 54 | 0.17 | Why? |
| Albuminuria | 1 | 2018 | 164 | 0.17 | Why? |
| Cardiovascular Diseases | 3 | 2020 | 11497 | 0.17 | Why? |
| Fundus Oculi | 1 | 2017 | 237 | 0.16 | Why? |
| Renin-Angiotensin System | 3 | 2021 | 3661 | 0.15 | Why? |
| Myocardial Contraction | 1 | 2017 | 123 | 0.15 | Why? |
| Coronary Stenosis | 1 | 2019 | 273 | 0.15 | Why? |
| Microcirculation | 1 | 2019 | 447 | 0.14 | Why? |
| Cardiac Tamponade | 1 | 2018 | 165 | 0.14 | Why? |
| Risk Assessment | 2 | 2019 | 25439 | 0.14 | Why? |
| Microvessels | 1 | 2019 | 490 | 0.14 | Why? |
| Medication Therapy Management | 1 | 2018 | 312 | 0.14 | Why? |
| Treatment Outcome | 5 | 2018 | 51732 | 0.14 | Why? |
| Antiphospholipid Syndrome | 1 | 2020 | 533 | 0.14 | Why? |
| Retinal Vessels | 1 | 2017 | 255 | 0.14 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2018 | 604 | 0.13 | Why? |
| Drug Therapy, Combination | 2 | 2018 | 7268 | 0.13 | Why? |
| Pulmonary Embolism | 1 | 2013 | 4775 | 0.13 | Why? |
| Clinical Laboratory Services | 1 | 2020 | 781 | 0.13 | Why? |
| Ventilation-Perfusion Ratio | 1 | 2013 | 99 | 0.12 | Why? |
| Death, Sudden, Cardiac | 1 | 2018 | 522 | 0.12 | Why? |
| Humans | 32 | 2021 | 930598 | 0.12 | Why? |
| Prospective Studies | 5 | 2020 | 43301 | 0.11 | Why? |
| Morbidity | 1 | 2018 | 1426 | 0.11 | Why? |
| Thyroid Crisis | 1 | 2010 | 5 | 0.11 | Why? |
| Dilatation, Pathologic | 1 | 2011 | 78 | 0.11 | Why? |
| Posture | 1 | 2013 | 199 | 0.11 | Why? |
| Pulmonary Ventilation | 1 | 2013 | 152 | 0.11 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2018 | 830 | 0.11 | Why? |
| Perfusion Imaging | 1 | 2013 | 199 | 0.11 | Why? |
| Middle Aged | 15 | 2021 | 270681 | 0.11 | Why? |
| Survival Rate | 3 | 2020 | 9206 | 0.10 | Why? |
| Female | 19 | 2021 | 380317 | 0.10 | Why? |
| Aged | 17 | 2021 | 215776 | 0.10 | Why? |
| Coronary Angiography | 1 | 2019 | 2275 | 0.10 | Why? |
| Male | 17 | 2021 | 367725 | 0.09 | Why? |
| Predictive Value of Tests | 3 | 2019 | 9537 | 0.09 | Why? |
| Hemodynamics | 1 | 2017 | 1562 | 0.09 | Why? |
| Stroke Volume | 1 | 2018 | 2153 | 0.09 | Why? |
| Aorta | 1 | 2011 | 355 | 0.09 | Why? |
| Hematologic Neoplasms | 1 | 2020 | 2105 | 0.08 | Why? |
| Prevalence | 3 | 2018 | 25773 | 0.08 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.08 | Why? |
| Acute Coronary Syndrome | 1 | 2020 | 2107 | 0.08 | Why? |
| Smartphone | 1 | 2017 | 1840 | 0.08 | Why? |
| Analysis of Variance | 2 | 2021 | 950 | 0.08 | Why? |
| Reproducibility of Results | 2 | 2019 | 11304 | 0.07 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.07 | Why? |
| Time Factors | 2 | 2018 | 31397 | 0.07 | Why? |
| Sex Factors | 2 | 2020 | 11014 | 0.07 | Why? |
| Health Status | 1 | 2018 | 3259 | 0.07 | Why? |
| Coronary Artery Disease | 1 | 2019 | 2570 | 0.07 | Why? |
| Societies, Medical | 1 | 2020 | 6907 | 0.07 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.06 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.06 | Why? |
| Emergencies | 1 | 2018 | 4095 | 0.06 | Why? |
| Ultrasonography | 1 | 2019 | 4409 | 0.06 | Why? |
| Aging | 1 | 2019 | 3581 | 0.06 | Why? |
| Myocardial Infarction | 1 | 2018 | 3361 | 0.06 | Why? |
| Ambulatory Care | 1 | 2019 | 4947 | 0.06 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.06 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.05 | Why? |
| beta 2-Glycoprotein I | 1 | 2020 | 92 | 0.05 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.05 | Why? |
| Phosphatidylserines | 1 | 2020 | 99 | 0.05 | Why? |
| Prothrombin | 1 | 2020 | 149 | 0.05 | Why? |
| Dyspnea | 1 | 2013 | 3847 | 0.05 | Why? |
| Mycoplasma pneumoniae | 1 | 2021 | 233 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.05 | Why? |
| Urinalysis | 1 | 2020 | 218 | 0.05 | Why? |
| Vascular Resistance | 1 | 2019 | 148 | 0.05 | Why? |
| Adult | 8 | 2021 | 244371 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.04 | Why? |
| Hypoxia | 1 | 2013 | 3626 | 0.04 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.04 | Why? |
| Ophthalmoscopy | 1 | 2017 | 65 | 0.04 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.04 | Why? |
| Age Factors | 4 | 2021 | 21039 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2019 | 15421 | 0.04 | Why? |
| Prognosis | 4 | 2020 | 32490 | 0.04 | Why? |
| Luminescent Measurements | 1 | 2020 | 924 | 0.04 | Why? |
| Multimorbidity | 1 | 2020 | 703 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| Photography | 1 | 2017 | 255 | 0.04 | Why? |
| Cross-Sectional Studies | 5 | 2021 | 53120 | 0.03 | Why? |
| Calcium Channel Blockers | 1 | 2017 | 367 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.03 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.03 | Why? |
| Hospitals, Teaching | 1 | 2020 | 1609 | 0.03 | Why? |
| Body Surface Area | 1 | 2011 | 50 | 0.03 | Why? |
| Methimazole | 1 | 2010 | 12 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.03 | Why? |
| Antithyroid Agents | 1 | 2010 | 28 | 0.03 | Why? |
| Ferritins | 1 | 2020 | 2055 | 0.03 | Why? |
| Bisoprolol | 1 | 2010 | 65 | 0.03 | Why? |
| Cerebrovascular Disorders | 1 | 2019 | 1040 | 0.03 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.03 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.02 | Why? |
| Epitopes | 1 | 2020 | 4113 | 0.02 | Why? |
| Muscle Weakness | 1 | 2010 | 406 | 0.02 | Why? |
| Adrenergic beta-Antagonists | 1 | 2010 | 465 | 0.02 | Why? |
| Chronic Disease | 1 | 2021 | 5139 | 0.02 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.02 | Why? |
| Guideline Adherence | 1 | 2019 | 2309 | 0.02 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.02 | Why? |
| Abdominal Pain | 1 | 2010 | 858 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.02 | Why? |
| Databases, Factual | 1 | 2019 | 6248 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Practice Patterns, Physicians' | 1 | 2019 | 4927 | 0.01 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.01 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.01 | Why? |
| Animals | 1 | 2019 | 78931 | 0.01 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.01 | Why? |
Salvetti's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(162)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(158)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_